• Donate
  • Contact
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
  • About Pompe
    • Diagnosing Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Resources
    • Pompe – How to
    • Links
    • Connections
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
  • About Pompe Disease
  • Diagnosing Pompe Disease
    • Talk Pompe
    • Webinars
  • Blog
  • Resources
    • Pompe – How to
    • Links
    • Connections
  • Donate
  • Contact
Emerging From the Pandemic: Pompe Perspectives

Emerging From the Pandemic: Pompe Perspectives

by CAP | Jun 20, 2021 | Webinars

Dr Aneal Khan, Alexandra Butler, Sherry Simo and Lochlan Smyth will recap and look forward to emerging from the pandemic.

Virtual Town Hall: Being Rare in a Pandemic

Virtual Town Hall: Being Rare in a Pandemic

by CAP | Jun 19, 2020 | Webinars

A Q&A with Dr Aneal Khan, MSc, MD, FRCPC, FCCMG; Professor of Medical Genetics and Pediatrics, University of Calgary, Alberta Children’s Hospital.

Sanofi Genzyme COVID-19 Update

Sanofi Genzyme COVID-19 Update

by CAP | Mar 28, 2020 | COVID-19

At this time, Sanofi Genzyme does not anticipate shortages for patients resulting from the COVID-19 situation.

Amicus Therapeutics’ Clinical Trials During the COVID-19 Outbreak

Amicus Therapeutics’ Clinical Trials During the COVID-19 Outbreak

by CAP | Mar 19, 2020 | COVID-19

Patients enrolled in all clinical studies for AT-GAA for Pompe disease, including the PROPEL pivotal study, will continue to receive study drug.

Recent Posts

  • Nexviazyme Meets All Endpoints in Phase 3 Study for Infantile-Onset Pompe Disease
  • First Participant Dosed in Phase 1/2 Gene Therapy Trial for Late-Onset Pompe Disease
  • First Patients Enrolled in Phase 2 Trial of SRT for Late-Onset Pompe Disease
  • Aro Biotherapeutics reports positive phase 1b results for ABX1100
  • 2025 Pompe Empowerment Workshop : Vancouver
  • Terms
  • Privacy
Copyright © 2006 -2026 Canadian Association of Pompe
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.